| Basic data |
|---|
| OCA1. Surname awarded to the assessed person | Čurlík |
|---|
| OCA2. Name awarded to the assessed person | Ján |
|---|
| OCA3. Degrees awarded to the assessed person | Assoc. prof. , DVM, PhD |
|---|
| OCA4. Hyperlink to the entry of the person in the Register of university staff | https://www.portalvs.sk/regzam/detail/6068 |
|---|
| OCA5. Area of assessment | study programme parasitic diseases of animals · III. degree |
|---|
| OCA6. Category of the research/artistic/other output | scientific output |
|---|
| OCA7. Year of publication of the research/artistic/other output | 2022 |
|---|
| OCA8. ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) | 475257 |
|---|
| OCA9. Hyperlink to the record in CRPA or CRAA | https://app.crepc.sk/?fn=detailBiblioFormChildG74I1&sid=BB8EFC728647E64BA30489EA9C&seo=CREP%C4%8C-detail-%C4%8Cl%C3%A1nok |
|---|
| Characteristics of the output that is not registered in CRPA or CRAA |
|---|
| OCA10. Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs | https://pubmed.ncbi.nlm.nih.gov/35432292/ |
|---|
| OCA11. Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs | Jana Hruškovicová, Katarína Bhide, Patrícia Petroušková, Zuzana Tkáčová, Evelína Mochnáčová, Ján Čurlík, Mangesh Bhide, Amod Kulkarni: Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein. In Front Microbiol. 2022 Apr 1:13:801466. doi: 10.3389/fmicb.2022.801466. eCollection 2022.
Engineering the single domain antibodies targeting receptor binding motifs within the domain III of West Nile Virus envelope glycoprotein. |
|---|
| OCA12. Type of the output (if the output is not registered in CRPA or CRAA) | article |
|---|
| OCA13. Hyperlink to the webpage where the output is available (full text, other documentation, etc.) | https://pubmed.ncbi.nlm.nih.gov/35432292/ |
|---|
| OCA14. Characteristics of the author's contribution | Co-author of the publication, expert in the field. |
|---|
| OCA15. Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. | West Nile virus (WNV) is a mosquito-borne neurotrophic flavivirus causing mild febrile illness to severe encephalitis and acute flaccid paralysis with long-term or permanent neurological disorders. Due to the absence of targeted therapy or vaccines, there is a growing need to develop effective anti-WNV therapy. In this study, single-domain antibodies (sdAbs) were developed against the domain III (DIII) of WNV\'s envelope glycoprotein to interrupt the interaction between DIII and the human brain microvascular endothelial cells (hBMEC). |
|---|
| Other data |
|---|
| OCA16. Annotation of the output in English | West Nile virus (WNV) is a mosquito-borne neurotrophic flavivirus causing mild febrile illness to severe encephalitis and acute flaccid paralysis with long-term or permanent neurological disorders. Due to the absence of targeted therapy or vaccines, there is a growing need to develop effective anti-WNV therapy. In this study, single-domain antibodies (sdAbs) were developed against the domain III (DIII) of WNV\'s envelope glycoprotein to interrupt the interaction between DIII and the human brain microvascular endothelial cells (hBMEC). |
|---|
| OCA17. List of maximum 5 most significant citations corresponding to the output | Differential transcriptome response of blood brain barrier spheroids to neuroinvasive Neisseria and Borrelia. Kulkarni A, Jozefiaková J, Bhide K, Mochnaćová E, Bhide M. Front Cell Infect Microbiol. 2023 Dec 19;13:1326578. doi: 10.3389/fcimb.2023.1326578. eCollection 2023. PMID: 38179419
A review on camelid nanobodies with potential application in veterinary medicine. Tohidi E, Ghaemi M, Golvajouei MS. Vet Res Commun. 2024 Aug;48(4):2051-2068. doi: 10.1007/s11259-024-10432-x. Epub 2024 Jun 13. PMID: 38869749
Nanobodies: a promising approach to treatment of viral diseases. Minatel VM, Prudencio CR, Barraviera B, Ferreira RS Jr. Front Immunol. 2024 Jan 23;14:1303353. doi: 10.3389/fimmu.2023.1303353. eCollection 2023. PMID: 38322011 |
|---|
| OCA18. Characteristics of the output's impact on socio-economic practice | The peripheral blood mononuclear cells of the llama immunized with recombinant DIIIL297-S403 (rDIII) were used to generate a variable heavy chain only (VHH)-Escherichia coli library, and phage display was performed using the M13K07ΔpIII Hyperphages system. Phages displaying sdAbs against rDIII were panned with the synthetic analogs of the DIII receptor binding motifs, DIII-1G299-K307 and DIII-2V371-R388, and the VHH gene from the eluted phages was subcloned into E. coli SHuffle. Soluble sdAbs purified from 96 E. coli SHuffle clones were screened to identify 20 candidates strongly binding to the synthetic analogs of DIII-1G299-K307 and DIII-2V371-R388 on a dot blot assay. Among them, sdAbA1, sdAbA6, sdAbA9, and sdAbA10 blocked the interaction between rDIII and human brain microvascular endothelial cells (hBMECs) on Western blot and cell ELISA. |
|---|
| OCA19. Characteristics of the output and related activities' impact on the educational process | The published results will be used in the pedagogical process in exercises and lectures. |
|---|
